Screener
BioMarin Pharmaceuticals BMRN Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Royalty and other revenues | 5,315 | 12,428 | 11,445 | 22,929 |
| Total revenues | 989,708 | 825,410 | 1,755,916 | 1,570,555 |
| OPERATING EXPENSES: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| Research and development | 206,952 | 161,308 | 385,748 | 320,039 |
| Selling, general and administrative | 395,549 | 232,279 | 653,839 | 438,395 |
| Intangible asset amortization | 73,492 | 4,846 | 77,975 | 9,693 |
| Total operating expenses | 878,788 | 548,523 | 1,515,356 | 1,069,775 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's business segments — cost of sales?
- BioMarin Pharmaceuticals (BMRN) reported business segments — cost of sales of $202.8M in Q2 2026.
- How has BioMarin Pharmaceuticals's business segments — cost of sales changed year-over-year?
- BioMarin Pharmaceuticals's business segments — cost of sales increased by 35.1% year-over-year, from $150.09M to $202.8M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — cost of sales?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — cost of sales has grown at a 12.6% compound annual growth rate (CAGR), from $503.02M to $717.44M.
- What does business segments — cost of sales mean?
- This represents the direct costs attributable to the production and distribution of the products sold within the reportable segment. It includes manufacturing expenses, raw materials, and logistics costs required to bring therapies to market. Monitoring this helps evaluate the direct production efficiency of the segment's product portfolio.
Ask your AI about BioMarin Pharmaceuticals's business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude